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Pseudomonas aeruginosa is the predominant opportunistic bacterium that causes chronic 11 
respiratory infections in cystic fibrosis (CF) patients. This bacterium can form biofilms, which 12 
are structured communities of cells encased within a self-produced matrix. Such biofilms have 13 
a high level of resistance to multiple classes of antibiotics. A widely used treatment of P. 14 
aeruginosa lung infections in CF patients is tobramycin dry powder inhalation. The behaviour 15 
of particles in the lung has been well studied, and dry powder inhalers are optimised for optimal 16 
dispersion of the drug into different zones of the lung. However, one question that has not been 17 
addressed is whether the size of an antibiotic particle influences the antibiofilm activity against 18 
P. aeruginosa. We investigated this by fractionating tobramycin particles using a Next 19 
Generation Impactor (NGI).  The fractions obtained were then tested in an in vitro model on 20 
P. aeruginosa biofilms. The results indicate that the antibiofilm activity of tobramycin dry 21 
powder inhaler can indeed be influenced by the particle size. Against P. aeruginosa biofilms 22 
of two clinical isolates, smaller tobramycin particles (aerodynamic diameter <2.82 µm) showed 23 
better efficacy by approximately 20% as compared to larger tobramycin particles (aerodynamic 24 
diameter <11.7 µm) However, this effect was only observed when biofilms were treated for 3 25 
hours, whereas there was no difference after treatment for 24 hours. This suggests that in our 26 
model the rate of dissolution of larger particles limits the effectiveness of tobramycin over a 3-27 
hour time period, which is relevant as this is equivalent to the time in which most tobramycin 28 
is cleared from the lung.  29 
 30 
Keywords: Pseudomonas aeruginosa, biofilms, tobramycin, dry powder inhaler, Next 31 
Generation Impactor (NGI), particle size 32 
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1. Introduction  33 
In patients with cystic fibrosis (CF), the opportunistic pathogen Pseudomonas aeruginosa is a 34 
major cause of lung infections leading to increased morbidity and mortality rates among these 35 
patients. This is attributed partially to the ability of this bacterium to form biofilms (Ciofu et 36 
al., 2015; Muheim et al., 2017; Nikaido and Pagès, 2012). These biofilms are highly organized 37 
communities of cells that are attached to each other and/or to surfaces, and embedded within a 38 
self-synthesized extracellular polymeric substance (EPS) matrix, mainly containing 39 
extracellular DNA, polysaccharides, and/or proteins (Furiga et al., 2015). Biofilms are 40 
characterized by a high tolerance to both immune defensive mechanisms and to most of the 41 
available antibiotic therapies. For instance, it is assumed that cells inside biofilms are 10-1000 42 
times less susceptible to anti-microbial therapies as compared to planktonic free-floating cells 43 
(Marshall et al., 2016; Patton et al., 2010; She et al., 2018).  44 
P. aeruginosa biofilms in CF lungs settle and localise in a thick mucus layer in the trachea-45 
bronchial region of the respiratory airways (Geller et al., 2011). Such a location makes the 46 
treatment of these infections using the systemic delivery of antibiotic agents challenging, as 47 
high doses are required to reach the lung tissue which can lead to adverse reactions. Therefore, 48 
the pulmonary delivery of antibiotics is an attractive approach for the treatment of lung CF 49 
infections (Geller et al., 2011; Worlitzsch et al., 2002).   Inhaled antibacterial drugs that are 50 
used in the treatment of P. aeruginosa CF lung infections are in two forms, being either 51 
nebulized solutions or dry powder formulations (Ambrus et al., 2018). The currently approved 52 
inhaled dry powder antibiotics are colistin and tobramycin. For instance, TOBI Podhaler® is 53 
an approved dry powder inhalation formulation of tobramycin (McKeage, 2013; Akkerman-54 
Nijland et al, 2020), which most CF patients prefer when comparing to nebulised tobramycin, 55 
leading to, for instance, better adherence (Harrison et al., 2014). Tobramycin powder from a 56 
capsule is aerosolized using the Podhaler device by the energy of the patient’s own inspiration 57 
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(Konstan et al., 2011), resulting in the particles in the powder being separated from each other 58 
and carried in the airstream to the lungs where they deposited.   59 
Following inhalation, these particles distribute and deposit into different compartments of the 60 
lung. Briefly, the lung can be divided into two regions, the conducting and the respiratory 61 
zones. The conducting zone includes trachea, bronchi, bronchioles, and terminal bronchioles, 62 
whereas the respiratory zone comprises of the respiratory bronchioles, alveolar ducts and 63 
alveolar sacs (Hoiby, 2011). Deposition of dry powder particles in these zones depends on 64 
several variables such as patient-associated factors, the inhaler device and inhaled powder 65 
formulation properties (Tiddens et al., 2014) such as particle shape, density and size.  66 
Drug particle size is one of the important properties that can influence both the deposition and 67 
fate of particles in the respiratory airways. Normally, inhaled drug particles are polydisperse 68 
in nature with a large particle size range (Deng et al., 2018). Particles with an aerodynamic 69 
diameter (dae) larger than 10 µm are mostly deposited in the oropharyngeal region and do not 70 
reach the lungs, and those that are between 3-10 µm are mostly deposited in the trachea-71 
bronchial region. Furthermore, particles at a range of 1-3 µm target the alveolar zone of the 72 
lungs (Geller et al., 2011; Nafee et al., 2014; Verbanck et al., 2006), but those that even smaller 73 
(<1 µm) are exhaled due to low inertial and gravitational forces which are insufficient to 74 
deposit them (Nafee et al., 2014). Once deposited, the particles must dissolve and the rate of 75 
this depends on the size of these particles, which in turn can influence drug efficacy (Nafee et 76 
al., 2014).  77 
Currently, studies that evaluate the in vitro activity of tobramycin rely on testing its efficacy 78 
against P. aeruginosa biofilms in an aqueous solution. However, there are no biofilm models 79 
to test dry powder formulations, and it is thus unclear what the effect of, for instance, particle 80 
size is on antibiofilm activity, highlighting the need for a model that can address such issues. 81 
To achieve this, we used a Next Generation Impactor (NGI), which is an instrument used to 82 
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measure in vitro behaviour of inhalable dry powder products (Rowland et al., 2018). The NGI 83 
sequentially separates drug aerosols into various size categories from larger to smaller particles 84 
on the basis of the particles’ aerodynamic diameter (Guo et al., 2008; Roberts and Mitchell, 85 
2013; Wang et al., 2017). The cut-off aerodynamic diameters of these particles were previously 86 
determined at flow rates of 30 and 60 L/min (Marple et al., 2003). Using the NGI and a recently 87 
developed aerosol dose collection apparatus, we fractionated tobramycin particles into 88 
different sizes and tested these on a P. aeruginosa biofilm models to (a), test the feasibility of 89 
analysing dry powders on biofilms and (b), to further understand the role of particle size on 90 
antibiotic efficacy, which could be very valuable for improving the pharmacological activity 91 















2. Materials and Methods 93 
2.1 Chemicals 94 
All chemicals and culture media were purchased from Sigma-Aldrich (Gillingham, UK) or 95 
Fisher Scientific (Loughborough, UK), unless stated otherwise.  The TOBI Podhaler® and 28 96 
mg tobramycin inhalation powder (TIP) capsules were purchased from Novartis 97 
Pharmaceuticals (Camberley, UK). Tobramycin that was used to determine the minimal 98 
inhibitory concentration (section 2.3) and a calibration curve (section 2.8) was purchased from 99 
Fisher Scientific (97% purity). 100 
 101 
2.2 Bacterial strains and growth media  102 
The bacterial strains used in this study are laboratory strain P. aeruginosa PAO1 (Stover et al., 103 
2000) and three clinical CF isolates LMG 27648, LMG 27643, and LMG 27649. These clinical 104 
P. aeruginosa isolates were obtained from the Belgian Coordinated Collections of 105 
Microorganisms (BCCM, Brussels, Belgium). Strains were routinely grown on Mueller Hinton 106 
(MH; Oxoid) broth. Artificial sputum media (ASM) and minimal MOPS medium (MMM) 107 
were prepared as described elsewhere (Kirchner et al., 2012; LaBauve and Wargo, 2012). 108 
 109 
2.3 Minimum inhibitory concentration (MIC) 110 
MIC tests were performed in MH, MMM and ASM using the macro-dilution protocol as 111 
described elsewhere (Andrews, 2001). The MIC is defined as the lowest concentration of an 112 
antibiotic agent that shows no visible growth of a microorganism after overnight incubation. 113 
 114 
2.4 Colony biofilm assay 115 
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Colony biofilms of P. aeruginosa were grown as described (Merritt et al., 2005). Briefly, sterile 116 
semipermeable polycarbonate membranes (Whatman, Little Chalfont, UK; 0.2 µm pore size, 117 
25 mm) were placed on the surface of MH agar plates. Then an aliquot of 50 µl of overnight 118 
culture, adjusted to an optical density (OD) at 600 nm of 0.05, was spotted on each membrane. 119 
After that, the inoculated membranes were incubated for 48 h at 37°C to permit biofilm 120 
formation. The polycarbonate membranes were moved to fresh agar plates with sterile forceps 121 
on a daily basis. On the third day, a 30 µg tobramycin disc (Oxoid), or a glass fibre filter with 122 
TIP of various sizes (see section 2.6) were placed on the biofilms using sterile forceps. In case 123 
of the glass fibre filter, TIP particles were in direct contact with the top of the biofilms, and 124 
controls were covered with a filter without tobramycin. A schematic of the colony biofilm with 125 
tobramycin filter is shown in Figure 1. The biofilms were then incubated for a further 3 h or 126 
24 h, after which cells were harvested by resuspension in 5 mL of sterile phosphate buffered 127 
saline (PBS). Cells were dispersed by vigorously vortexing, and the colony forming units were 128 
determined by serial dilution and plating.  129 
 130 
2.5 Tobramycin capsule filling and humidity control 131 
To collect similar amounts of TIP with different particle sizes, we adjusted the mass of TIP 132 
aerosolised into the NGI. Before each experiment, hydroxypropyl methylcellulose capsules 133 
(HPMC; transparent; size #3; Capsugel, Colmar, France) were filled manually with TIP 134 
extracted from TOBI Podhaler® capsules and weighed using a four-place analytical balance 135 
(Sartorius, Epsom, UK). Initial experiments found unacceptable variation in NGI deposition 136 
when capsules were filled immediately before use. Therefore, capsules were stored for 24 h in 137 
a sealed desiccator under a controlled temperature of 25°C and relative humidity (RH) of 43% 138 
before testing, resulting in acceptable reproducibility. This RH was produced using a saturated 139 
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salt solution of potassium carbonate (K2CO3) (Miller et al., 2017). Temperature and relative 140 
humidity were monitored using a thermohygrometer placed inside the desiccator, and the 141 
following day these capsules were aerosolised through the NGI as described below (section 142 
2.6). 143 
 144 
2.6 Operation of the NGI 145 
The NGI was used by applying conditions described elsewhere (Meenach et al., 2013). Briefly, 146 
before testing, the pre-separator was filled with 15mL Milli-Q water. The NGI stages were 147 
coated with a solution of 1% (v/v) glycerol in methanol (VWR Chemicals) to minimize particle 148 
bounce. The NGI was connected to twin vacuum pumps (GAST 1023 series, connected in 149 
parallel) via a critical flow controller (TPK, Copley, Nottingham, UK), which was fixed before 150 
each experiment at 30 L/min or 60 L/min flow rates using a digital flow meter (DFM2000, 151 
Copley Scientific, Nottingham, UK). A TIP capsule for each experiment was aerosolised from 152 
a Podhaler through the NGI for 10 seconds, which was chosen as it is sufficient for complete 153 
dispersion of the powder from the capsule.  154 
Initial experiments were carried out to determine the aerodynamic particle size distribution of 155 
TIP when aerosolised from the Podhaler at 30 L/min and 60 L/min. These experiments utilised 156 
all eight stages of the NGI and the aerosolization of 28 mg TIP from a single as supplied TOBI 157 
capsule (n=5). Following each aerosolization, the mass of tobramycin collected on the 158 
induction port, pre-separator, stages 1 to 7, and MOC was determined (section 2.8). 159 
Subsequently, TIP particles of different sizes were collected from either stage 2 or 4 using an 160 
Aerosol Dose Collection (ADC) device (Price et al., 2020). The ADC allows particles to be 161 
collected on a glass fibre filter without the formation of in situ agglomerates, which can affect 162 
their subsequent dissolution behaviour. In the experimental set up with the ADC, a rubber 163 
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stopper was placed in the NGI air outlet from stage 2 or stage 4 to disrupt airflow and ensure 164 
the collection of all TIP particles on the filter. Second, a glass fibre filter (Copley®, 25 mm 165 
diameter, 1 µm pore size) was mounted in the ADC to collect TIP particles. The glass fibre 166 
filter was replaced for each repeat of the experiment and the flow rate was adjusted for each 167 
experiment after placing the filter in the ADC. These filters were either applied directly to 168 
biofilms (section 2.4), particles were visualised by electron microscopy (section 2.7), or the 169 
mass of TIP collected was determined (section 2.8). 170 
 171 
2.7 Scanning Electron Microscopy (SEM) 172 
To demonstrate that the ADC apparatus had successfully captured TIP particles of different 173 
sizes, their geometric particle size distribution was determined using SEM. TIP particles on 174 
glass fibre filters were analysed by applying conditions stated elsewhere (Li et al., 2014). TIP 175 
samples were fixed into aluminium stubs (Agar Scientific, Stansted, UK) using double-sided 176 
adhesive carbon tabs (Agar Scientific). Then, the samples were coated with a thin film of gold 177 
using a sputter coater (Sputter Coater S 150B, Edwards, Burgess Hill, UK). The coating process 178 
was operated at 1 kV of voltage for 3 min. The images were captured using Jeol SEM (Jeol 179 
Jsm-6480LV Scanning Electron Microscope; Jeol Ltd, Welwyn Garden City, UK), and several 180 
magnifications levels were used. The captured images were further analysed for geometric 181 
particle size determination using the software package ImageJ (Schneider et al., 2012). For 182 
every ImageJ analysis, manual particle size measurements were performed, and for every 183 
measurement fixed criteria were used: all particles in the given image might be measured, even 184 
the small particles in front of large particles; a specific number (100) of particles were selected 185 
randomly and the same magnification (x5000) was used for all images. As TOBI Podhaler® 186 
particles are spherical (McKeage, 2013), particle size was not sensitive to the direction of 187 
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measurement, so all diameters were measured in the vertical direction. Particle size 188 
distributions were summarised by the median diameter and span, which was defined the 189 
difference between the ninetieth and tenth centile diameters, divided by the median diameter. 190 
 191 
2.8 High Performance Liquid Chromatography-Mass Spectrometry (HPLC-MS) 192 
quantification 193 
To determine the mass of tobramycin collected on parts of the NGI or glass fibre filters, they 194 
were rinsed with known volumes of Milli-Q water and sonicated for 10 min in an ultrasonic 195 
water bath to ensure complete dissolution of TIP. To quantify the amount of tobramycin, an 196 
HPLC-MS method was developed and validated. The chromatographic system consisted of a 197 
pentafluoro phenyl F5 column (2.6 µM, 2.1 x 100 mm; Phenomenex, Macclesfield, UK) as the 198 
stationary phase, which was used with a flow rate of 0.3 mL/min at 25°C and an injection 199 
volume of 10 µL of each sample was injected in triplicate. The mobile phase involved utilizing 200 
two solvents, which were 100% water with 0.1% (v/v) formic acid as solvent A and 100% 201 
methanol with 0.1% (v/v) formic acid as solvent B. The proportion of these solvents in the 202 
mobile phase was controlled during the analysis by the ultra HPLC instrument. Elution was 203 
carried out with 0% mobile phase B for 3 min followed by a linear gradient to 100% B for 7 204 
min.  The mass spectrometer (Bruker Daltonik GmbH, Bremen, Germany) was operated in 205 
electrospray time of flight (ESI) positive-ion MS mode, and the following conditions were used 206 
during the MS analysis. The capillary voltage was set to 4500 V, nebulizing gas at 4 bar, and 207 
drying gas at 12 L/min at 220°C. The concentration of tobramycin in injected samples (and 208 
thus the mass of deposited tobramycin) was determined by constructing a calibration curve 209 
using kanamycin as an internal standard. Following the addition of kanamycin (final 210 
concentration 4 µg/mL), samples were vigorously vortexed prior to HPLC-MS analysis. All 211 
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stock solutions were prepared on the same day of the experiment, and HPLC-MS analysis was 212 
performed with 24 h. The calibration curve was linear (r2= 0.998) over the range of 5 to 20 213 
µg/ml. Based on the standard deviation of y-intercepts of the regression line (International 214 
Conference on Harmonisation, 1996), the estimates for the limit of detection was 1.4 µg/ml 215 
and the limit of quantification was 4.4 µg/ml. 216 
  217 
2.10 Statistical analysis 218 
Data were presented as the mean ± standard error of the mean (SEM) of n ≥ 3 independent 219 
biological repeats. Results were analysed using GraphPad Prism 7 by applying the Student t-220 
test. Values of p< 0.05 were considered statistically significant.  221 
  222 
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3. Results 223 
3.1 The in vitro activity of tobramycin against P. aeruginosa  224 
The MICs (Table 1) of tobramycin against one laboratory strain (P. aeruginosa PAO1) and 225 
three clinical CF isolates (P. aeruginosa LMG 27648, LMG 27643, and LMG 27649) were 226 
determined in MH broth, MMM and ASM by the macro-dilution method. The results showed 227 
that MIC values in in MH broth and MMM were fairly similar and differed by at most one 228 
doubling dilution, in the range of 0.25-1 µg/mL The MIC was, for all four strains, 4 µg/mL 229 
when ASM was used. All strains were susceptible to tobramycin according to BSAC 230 
breakpoints.  231 
To determine the activity of tobramycin against P. aeruginosa biofilms, which is the state that 232 
the cells are in during a lung infection, a colony biofilm assay was used. This model was chosen 233 
as the biofilm grow on a semi-solid surface with an air interface, which is probably more 234 
representative of biofilms in the lung as compared to the more standard 96-well plate assay in 235 
which biofilms are completely immersed in liquid. The results showed that in all tested strains, 236 
tobramycin reduced the viable count in the biofilms moderately (Fig 2). However, complete 237 
eradication was not achieved and the reduction in viable count was, on average, approximately 238 
60%.  239 
 240 
3.2 Aerodynamic particle size distribution of tobramycin inhalation powder 241 
The aerodynamic particle size distributions of TIP aerosolised from the Podhaler at both 30 242 
L/min and 60 L/min are shown in Fig 3. 243 
 244 
3.3 Tobramycin masses collected with the ADC mounted on stages 2 or 4 of the NGI 245 
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To determine the effect of particle size on eradication of P. aeruginosa biofilms, it was 246 
necessary to collect the same amount of TIP but with different particle sizes. The parameters 247 
to obtain approximately 0.5 mg TIP per filter were determined in an empirical manner. To this 248 
purpose we used the ADC mounted onto the NGI and determined that, at stage 2 at 30 L/min 249 
and TIP capsule mass of 4.4 mg, we collected a very similar mass as when using stage 4 at 60 250 
L/min and TIP capsule mass of 4.3 mg. This resulted in a mean mass of 0.51 mg with SD value 251 
of 0.05 for larger particles (stage 2 at 30 L/min, dae<11.7 µm) and 0.48 mg with SD value of 252 
0.12 for smaller particles (stage 4 at 60 L/min, dae<2.82 µm), with a difference between those 253 
masses of 7.8%. Statistically, the difference between the masses was not significant (p=0.15).  254 
 255 
3.4 SEM analysis  256 
Before testing fractionated tobramycin particles on biofilms, a number of tests were performed. 257 
Firstly, SEM analysis was used to image TIP particles that had been extracted from the NGI 258 
stages using the method outlined in section 2.6. These SEM images were further analysed to 259 
obtain geometric particle size measurements using ImageJ software. Representative SEM 260 
micrographs for TIP particles (Fig 4) show polydisperse, approximately spherical, and porous 261 
microparticles. The geometric particle size distributions determined from these images, using 262 
ImageJ, were approximately log-normal (Fig 5) and showed that on stage 2 at 30 L/min, the 263 
particle size distribution included some coarse particles, with a median geometric diameter of 264 
5.6 µm and span of 1.5. The particles collected at stage 4 at 60 L/min had a smaller median 265 





3.5 The influence of differently sized tobramycin inhalation powder particles against P. 269 
aeruginosa biofilms  270 
The fractions of small and large TIP particles were used to challenge P. aeruginosa biofilms. 271 
These were treated with a dose of 0.5 mg/filter TIP, and filters without tobramycin were used 272 
as control. The biofilms were incubated for 3 h, as this period is comparable to the time it takes 273 
for tobramycin sputum concentrations to be significantly reduced in people with CF (Hubert et 274 
al., 2009; Poli et al., 2007). The 3 h treatment time was not particularly effective in killing cells 275 
in our biofilm model but, crucially, there was an approximate 20% reduction of the viable count 276 
when applying particles with dae<2.82 µm as compared with particles with dae<11.7 µm (Fig 277 
6). For P. aeruginosa LMG27649 and LMG27643, particles with dae<11.7 µm did not have 278 
any effect on the biofilms, but there was a statistically significant (LMG27649: p=0.04; 279 
LMG27643: p=0.02) reduction with particles with dae<2.82 µm. For the other two strains, 280 
larger particles had a moderate effect on the viable count of cells in biofilms and there was a 281 
further reduction in viable count when the biofilms were treated with smaller particles. 282 
However, in the latter cases this reduction was statistically not significant (LMG27648: 283 
p=0.26; PAO1: p=0.63). 284 
The reduction in viable count after a 3 h treatment of the biofilms was rather poor, so we also 285 
tested the effect of a 24 h incubation with TIP. In this case, the reduction in viable count was 286 
between 80-90% when comparing samples with the untreated control (Fig 7). However, there 287 
was no significant difference in viable count reduction when comparing small and large TIP 288 
particles.  289 
  290 
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4. Discussion 291 
We investigated the influence of differently sized TIP particles against P. aeruginosa biofilms 292 
by making use of the NGI to separate particles into different fractions. These particles were 293 
collected from stage 2 at 30 L/min and stage 4 at 60 L/min, meaning that the collected fractions 294 
had dae<11.7 µm and dae<2.82 µm, respectively (Marple et al., 2003). The efficiency of the 295 
NGI and ADC device at capturing particles of different size ranges was confirmed by the SEM 296 
analysis, which found particles captured at stage 2 at 30 L/min had a larger median geometric 297 
diameter (5.6 µm) than those captured at stage 4 at 60 L/min (1.4 µm). 298 
An aerosol collection apparatus was used to collect TIP particles from the above-mentioned 299 
stages. Without this, deposition of particles from the NGI occurs directly on a solid impactor 300 
stage with high-speed deposition of particles in a small area, which results in the formation of 301 
strong agglomerates which then behave as larger particles (Price et al., 2020). However, using 302 
the ADC apparatus enables a slow and uniform deposition of aerosol particles over a single, 303 
large surface area glass fibre filter, so the collected powder subsequently behaves as single 304 
particles. 305 
A difficult issue to resolve was that the NGI separates powder into size fractions with different 306 
masses for each fraction, while equal masses were required to analyse the effect of particle size 307 
only. Moreover, the amount of tobramycin collected did not vary in a linear fashion with the 308 
aerosolised dose, so was difficult to predict. We essentially had to use a trial and error process 309 
to determine the parameters to collect equal masses of differently sized particles. Another issue 310 
was that initially the mass of TIP collected from the ADC device was variable, but results 311 
became more consistent when capsules were equilibrated at a constant humidity and 312 
temperature, before use.  313 
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When antibiotic particles are deposited on a biofilm, they must first dissolve in order to exert 314 
their pharmacological activity. This depends on particle size, which is one of the parameters 315 
that determines physical properties of a drug (Shekunov et al., 2007; Wang et al., 2017). 316 
Accordingly, the influence of TIP particles was investigated by testing differently sized 317 
particles for 3 and 24 h. At 24 h, there was a significant reduction in the viable count when 318 
comparing treated with untreated samples, but there was no difference between smaller and 319 
larger particles. Thus, over 24 h the difference in the rate of dissolution of small and large TIP 320 
particles is not a rate limiting step. However, this time is not physiologically relevant, as 321 
tobramycin sputum concentrations are significantly reduced after just 3 h in people with CF 322 
(Hubert et al., 2009; Poli et al., 2007), with the TOBI Podhaler having a sputum half-life of 323 
only 1-2 hours (Geller et al., 2007). An incubation time of 3 h was thus more appropriate. This 324 
time period was far less effective in reducing the viable count but, importantly, smaller particles 325 
were more effective by approximately 20% when compared to larger particles. Indeed, it is 326 
generally recognized that the dissolution rate of small-sized particles can be significantly better 327 
than the larger-sized particles, which is attributed to the larger specific surface area of the small 328 
particles (Riley et al., 2012; Tay et al., 2018; van der Wiel et al., 2017; Watts and Williams, 329 
2011). We should note, however, that while we observed a difference in the effectivity between 330 
small and large particles for all P. aeruginosa strains, it was statistically significant only for 331 
the two clinical isolates that were the most recalcitrant to a 3 h treatment, (LMG27649 and 332 
LMG27643). In these strains, larger particles did not cause any reduction in the viable count, 333 
while small particles resulted in a 20% reduction. In case of the other strains (LMG27648 and 334 
PAO1), larger particles resulted in approximately 15-20% reduction in viable count, with a 335 
further non-significant reduction with smaller particles. Planktonic cells of those four strains 336 
all displayed the same sensitivity to tobramycin, but phenotypic and genetic differences 337 
between the strains could result in the differences in biofilm formation, such as in composition 338 
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of the extracellular matrix or thickness of the biofilms (Wimpenny et al., 2000). For example, 339 
the three clinical isolates are reported to be alginate producers (Hoffmann et al., 2005; Leitão 340 
et al., 1996; Mathee et al., 2008), whereas the laboratory strain PAO1 does not produce this 341 
polysaccharide. We also observed that only LMG 27649 was unable to grow in a minimal 342 
growth medium without the addition of casamino acids (data not shown), indicating that this 343 
strain is auxotrophic, whereas the other strains are not. Whether this would influence the effects 344 
of tobramycin particles is not known, but it does clearly show that the strains differ from each 345 
other. 346 
The influence of differently sized particles of other drugs has been evaluated previously, 347 
showing better efficacy for smaller sized particles as compared to larger (Jinno et al., 2006; 348 
Leach et al., 2009; Liu et al., 2015). For example, for the oral vasodilator cilostazol, smaller 349 
cilostazol particles of 2.4 µm had a better rate of dissolution and efficacy than particles of 13 350 
µm (Jinno et al., 2006). This was also observed for inhaled beclomethasone (a corticosteroid), 351 
which is more effective in a particle size of 1.1 µm as compared to 4 µm (Leach et al., 2009; 352 
Van Schayck and Donnell, 2004; Vanden Burgt et al., 2000). Although these differences have 353 
been attributed to varying lung deposition patterns with changing particle size, they may also 354 
have been influenced the faster dissolution rate of smaller particles. 355 
We should acknowledge that our study has limitations. Firstly, there was a slight difference in 356 
the TIP mass that were collected for small and large sized particles from different stages/flow 357 
rates. It was technically difficult to obtain equal masses of differently sized particles, in 358 
particular at the amounts required for biofilm assays (0.5 mg/filter). However, the difference 359 
in the amounts obtained was statistically not significant (p> 0.05). It should be noted that on 360 
average we collected slightly less (<8%) of the smaller particles, but these were nevertheless 361 
more effective, which only strengthens our conclusion that smaller particle sizes result in more 362 
efficient killing of cells in P. aeruginosa biofilms. 363 
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Another limitation is that with the NGI the maximum particle size that is collected on the filters 364 
can be controlled, but not the minimum particle size. Thus, while the average particle size 365 
differs between the collected fractions, there is some overlap in particle sizes and effects on 366 
antibiofilm activity could have been greater if it was technically possible to control both 367 
minimum and maximum sizes. Also, our SEM analysis only measured the diameters of a small 368 
number of particles (100). Despite this, we obtained log-normal particle size distributions (Fig 369 
5), so these data provide additional reassurance that the NGI and ADC device collected 370 
particles of different sizes. 371 
Our system used the in vitro colony biofilm model (Merritt et al., 2005). It is a simple model 372 
system but nevertheless it is useful as biofilm grows on a semi-solid surface with an air-373 
interface. It is of course not the same as the conditions found in a lung, but in this study, it was 374 
a more useful model than for instance the standard 96-well plate biofilm assay. It should also 375 
be noted that 0.5 mg/filter TIP as used here is actually a very large dose when compared to a 376 
therapeutic dose of 112 mg spread through the whole surface area of the lungs (Geller et al., 377 
2011). Future studies therefore need to focus on the use of models that, firstly, use an amount 378 
of antibiotic that better reflects clinical doses and, secondly, better mimic the in vivo lung 379 
pathological conditions. The latter could be achieved using, for instance, ex vivo models that 380 
use porcine lung samples (Harrison and Diggle, 2016), or in vivo models (Kukavica-Ibrulj and 381 
Levesque, 2008).  382 
Our hypothesis on the effect of particle size was only tested for one dry powder inhaled 383 
antibiotic, tobramycin. An important aim of our study was to establish a system to test dry 384 
powder inhalers on biofilms. This has now been achieved and has demonstrated that the particle 385 
size of inhaled dry powders can influence their anti-biofilm activity. These are the most 386 
significant aspects of these findings, as this tool can be used to test other antibiotics. Our system 387 
may be of particular relevance to the development of dry powder inhaled formulations of drugs 388 
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with a low aqueous solubility, as in this situation the differences between small and large 389 
particles may become more pronounced than for tobramycin (which is freely soluble in water). 390 
Investigation of this issue may therefore highlight additional ways to increase the effectiveness 391 
of poorly soluble inhaled drugs. Future research should also measure the dissolution rate of 392 
different antibiotic particle size fractions, to fully examine the potential relationship between 393 
anti-biofilm activity and particle dissolution.  394 
 
5. Conclusion 395 
Tobramycin dry powder inhaler is one of the most widely used inhaled antibiotics in the 396 
treatment of CF lung infections.  Here we showed that small TIP particles (dae<2.82 µm) 397 
showed better efficacy as indicated by a 20% reduction in the viable count as compared to 398 
larger particles (dae<11.7 µm) at an incubation time of 3 h against P. aeruginosa biofilms; this 399 
reduction was statistically significant for two strains of the four strain, but the trend was 400 
observed in all strains. This short incubation time is important, as this is the same timeframe in 401 
which tobramycin is largely cleared from the lung. These initial findings highlight that particle 402 
size can affect TIP antibiofilm activity. Importantly, we have developed a system to test the 403 
effect of dry powder inhalers on bacterial biofilms, and we are planning to utilise this to test 404 
other antibiotics and as well as employing more advanced biofilm models. 405 
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Table 1. The MICs (µg/mL) of tobramycin against P. aeruginosa clinical CF isolates and 579 
PAO1 determined in triplicate by macro-dilution method in MH, MMM and ASM media. 580 
 581 
P. aeruginosa strain MICs in MH MIC in MMM MICs in ASM 
LMG 27649 0.5 1 4 
LMG 27643 0.5 0.25 4 
LMG 27648 1 0.5 4 
PAO1 0.5 0.5 4 
 582 
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Figure legends 588 
Figure 1. Schematic of the colony biofilm. Cells were grown on a polycarbonate membrane to 589 
form a biofilm, and on the third day a filter with tobramycin inhalation powder was placed on 590 
top. After incubation for 3 or 24 hours, the cells were harvested and a viable count was 591 
determined. 592 
Figure 2. The in vitro activity of tobramycin against P. aeruginosa using the colony biofilm 593 
assay. (A – C) show clinical CF isolates and (D) indicates laboratory strain PAO1. All P. 594 
aeruginosa biofilms were grown for 48 h on MH agar, treated with 30 µg/disc tobramycin, and 595 
incubated for 24 h at 37°C. The controls represent biofilms without tobramycin. The data 596 
shown represent the standard error of the mean from three biological repeats and each 597 
biological repeat consisted of at least two technical repeats. Statistics were analysed using 598 
unpaired 2-tailed t test. Statistically significant differences between treated biofilms (***, 599 
p<0.001; ****, p<0.0001) and the control are indicated. 600 
Figure 3. Aerosol particle size distribution of tobramycin inhalation powder when aerosolised 601 
for 10 seconds from the Podhaler® device into the NGI at 30 L/min (A) and 60 L/min (B). 602 
Error bars represent the standard error of the mean from five independent experiments for each 603 
flow rate. Stages 1-7 indicate the impactor stages, followed by their corresponding cut off 604 
aerodynamic diameter in parentheses. MOC: micro-orifice collector. 605 
Figure 4. Representative SEM micrographs of TIP particles from NGI stages at different flow 606 
rates. Stage 2, at 30 L/min (A) and Stage 4, at 60 L/min (B). Pictures were taken at x4,000 607 
magnification (scale bar = 5 µm). 608 
Figure 5. Comparison of the cumulative geometric particle size distributions of tobramycin 609 
inhalation powder particles collected at stage 2 (A) and 4 (B) of the NGI at 30 L/min and 60 610 
L/min, respectively. 611 
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Figure 6. The influence of differently size TIP particles on the eradication of P. aeruginosa 612 
biofilms. (A-C) show clinical isolates, and (D) indicates the laboratory strain PAO1. Bacterial 613 
cells were grown as colony biofilms for 48 h at 37°C and then were treated with different 614 
tobramycin particle size fractions of dae<11.7 µm and dae<2.82 µm for 3 h. The data shown 615 
represent the standard error of the mean from three biological repeats and each biological repeat 616 
consisted of at least two technical repeats. Statistics were analysed using an unpaired 2-tailed 617 
t test. Statistically significant differences between large and small particles are indicated (*, 618 
p<0.05).  619 
Figure 7. The influence of differently sized TIP particles on the eradication of P. aeruginosa 620 
biofilms. (A-C) show clinical isolates, and (D) indicates the laboratory strain PAO1.  Bacterial 621 
cells were grown as colony biofilms for 48 h at 37°C and then were treated with different 622 
tobramycin particle size fractions of dae<11.7 µm and dae<2.82 µm for 24 h. The data shown 623 
represent the standard error of the mean from three biological repeats and each biological repeat 624 
consisted of at least two technical repeats. Statistical significance was analysed using an 625 
unpaired 2-tailed t test. 626 
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